Publications by authors named "Mayu Ohuchi"

Claim this Profile
E
Elevated mepolizumab levels in patients with severe asthma responsive to 1 year's mepolizumab treatment.
Takayasu Nishimaki, Hitoshi Sasano, Sonoko Harada, Tomohito Takeshige, Yuuki Sandhu, Mayu Ohuchi

J Allergy Clin Immunol Glob· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non-small-Cell Lung Cancer in Patients Aged 75 Years and Older.
Shigehiro Yagishita, Yuta Yamanaka, Takayasu Kurata, Kageaki Watanabe, Yukio Hosomi, Mayu Ohuchi

Clin Pharmacol Ther· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Pharmacokinetics, Effectiveness, and Safety of Atezolizumab in Patients With Unresectable Advanced or Recurrent NSCLC: An Exploratory Study of J-TAIL.
Shigehiro Yagishita, Yasushi Goto, Makoto Nishio, Hiroaki Akamatsu, Hidetoshi Hayashi, Mayu Ohuchi

JTO Clin Res Rep· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of ramucirumab pharmacokinetics in combination with docetaxel on the efficacy and survival in patients with advanced non-small cell lung cancer.
Kazumasa Akagi, Shigehiro Yagishita, Mayu Ohuchi, Yoshiharu Hayashi, Yuki Takeyasu

Lung Cancer· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC.
Hitomi Jo, Tatsuya Yoshida, Shigehiro Yagishita, Mayu Ohuchi, Yuji Matsumoto

JTO Clin Res Rep· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: A population pharmacokinetic analysis in real-world non-small cell lung cancer patients.
Mayu Ohuchi, Shigehiro Yagishita, Hitomi Jo, Kazumasa Akagi, Ryoko Inaba Higashiyama

Lung Cancer· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC.
Ryoko Inaba Higashiyama, Tatsuya Yoshida, Shigehiro Yagishita, Mayu Ohuchi, Naomi Sakiyama

J Thorac Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of an analytical method to determine E7130 concentration in mouse plasma by micro-sampling using ultra-performance liquid chromatography-high resolution mass spectrometry.
Shoraku Ryu, Yoshiharu Hayashi, Shigehiro Yagishita, Ako Takahashi, Akira Yokoi, Mayu Ohuchi

J Chromatogr B Analyt Technol Biomed Life Sci· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Augmented Clearance of Nivolumab Is Associated with Renal Functions in Chronic Renal Disease Model Rats.
Kazuaki Taguchi, Yukitaka Hayashi, Mayu Ohuchi, Hotaka Yamada, Shigehiro Yagishita

Drug Metab Dispos· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Visualization of Intratumor Pharmacokinetics of [fam-] Trastuzumab Deruxtecan (DS-8201a) in HER2 Heterogeneous Model Using Phosphor-integrated Dots Imaging Analysis.
Mikiko Suzuki, Shigehiro Yagishita, Kiyoshi Sugihara, Yusuke Ogitani, Tadaaki Nishikawa, Mayu Ohuchi

Clin Cancer Res· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A procedure for method development and protein binding ratio as the indicator of sensitivity with anticancer agents on MALDI mass spectrometry imaging.
Yoshiharu Hayashi, Mayu Ohuchi, Shoraku Ryu, Shigehiro Yagishita, Akinobu Hamada

Drug Metab Pharmacokinet· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of an alternative signature peptide during development of a LC-MS/MS assay of plasma nivolumab levels applicable for multiple species.
Mayu Ohuchi, Shigehiro Yagishita, Kazuaki Taguchi, Yasushi Goto, Masaru Fukahori

J Chromatogr B Analyt Technol Biomed Life Sci· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Visualization of the distribution of nanoparticle-formulated AZD2811 in mouse tumor model using matrix-assisted laser desorption ionization mass spectrometry imaging.
Shoraku Ryu, Mayu Ohuchi, Shigehiro Yagishita, Tatsunori Shimoi, Kan Yonemori

Sci Rep· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Long Half-Life of Programmed Cell Death Protein 1 Inhibitors May Increase the Frequency of Immune-Related Adverse Events After Subsequent EGFR Tyrosine Kinase Inhibitor Therapy.
Yuki Shinno, Yasushi Goto, Mayu Ohuchi, Akinobu Hamada, Hiroshi Nokihara

JTO Clin Res Rep· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-performance liquid chromatography-tandem mass spectrometry for simultaneous determination of raltegravir, dolutegravir and elvitegravir concentrations in human plasma and cerebrospinal fluid samples.
Kiyoto Tsuchiya, Mayu Ohuchi, Naoe Yamane, Hiroaki Aikawa, Hiroyuki Gatanaga

Biomed Chromatogr· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the heterogeneous tissue distribution of erlotinib in lung cancer using matrix-assisted laser desorption ionization mass spectrometry imaging.
Yukari Tsubata, Mitsuhiro Hayashi, Ryosuke Tanino, Hiroaki Aikawa, Mayu Ohuchi

Sci Rep· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis